J&J's Janssen un­veils PhII ul­cer­a­tive col­i­tis da­ta for Trem­fya com­bo, look­ing to ex­pand the drug's foot­print

3 years ago
R&D

A liv­er dis­ease up­start with some glob­al con­nec­tions and a new R&D strat­e­gy reaps a $30M launch round

3 years ago
Financing
R&D

The crown jew­el in Mer­ck’s $11.5B Ac­celeron buy­out just cleared a piv­otal PhI­II

3 years ago
R&D

BIO chief Mc­Mur­ry-Heath on leave as storm clouds gath­er over group’s di­rec­tion, leg­isla­tive set­back

3 years ago
People
FDA+

Taste of M&A Mon­day; A spe­cial kind of lab; Biotech founder wins No­bel; Bio­Marin lay­offs; and more

3 years ago
Weekly

CSL Se­qirus snaps up $30M+ BAR­DA con­tract to de­vel­op in­fluen­za vac­cine at its ex­pand­ed fa­cil­i­ty in NC

3 years ago
Pharma
Manufacturing

Servi­er adds a 's­mile' to its brand while set­ting am­bi­tious on­col­o­gy goals

3 years ago
Pharma
Marketing

No­var­tis shoots 'From the Heart' in new video se­ries to spur dis­cus­sions — and changes — in car­dio­vas­cu­lar ...

3 years ago
Pharma
Marketing

'False hopes': FDA re­leas­es brief­ing docs on con­tro­ver­sial preterm birth med Mak­e­na ahead of ad­comm

3 years ago
Pharma
FDA+

BioN­Tech al­lies with Aus­tralian state, ini­tial­iz­ing plans to con­struct new R&D and man­u­fac­tur­ing fa­cil­i­ties

3 years ago
Deals
Manufacturing

Al­ny­lam touts la­bel ex­pan­sion for rare ox­alate dis­ease

3 years ago
Pharma

Roche breaks ground on ex­pan­sion at New Jer­sey man­u­fac­tur­ing site

3 years ago
Manufacturing

Fred Hutch re­brands af­ter merg­er, blend­ing can­cer re­search and pa­tient care lega­cies in new iden­ti­ty

3 years ago
Pharma
Marketing

Ad­vo­cates pe­ti­tion FDA to make abor­tion pill ac­ces­si­ble to mis­car­riage pa­tients

3 years ago
Pharma
FDA+

Un­der the weight of a 2-year clin­i­cal hold, a biotech’s new board starts com­pa­ny re­view, ousts CEO

3 years ago
People

Math­ai Mam­men emerges as top can­di­date for Bio­gen CEO job — STAT

3 years ago
People

Amid al­ready plung­ing use of Mer­ck’s Covid-19 an­tivi­ral Lagevrio, preprint gives look in­to re­al world per­for­mance

3 years ago
R&D
Coronavirus

An AI, err ma­chine learn­ing, shop lines up Eli Lil­ly as part­ner ahead of first in-house clin­i­cal tri­al

3 years ago
Deals
AI

On­colyt­ic virus ex­perts at Replimune re­load with $200M loan as biotech col­lects clin­i­cal da­ta

3 years ago
Financing

Bio­Marin lays off 120 staffers to 'sim­pli­fy' the com­pa­ny while FDA re­views its big gene ther­a­py

3 years ago
People

Ris­ing from the IL-2 ash­es and dras­tic re­org, Nek­tar in merg­er talks with PureTech

3 years ago
Deals

Sanofi's BD chief heads to Owkin as CBO; Roche re­lies on its bench for Thomas Schi­neck­er’s di­ag­nos­tics re­place­ment

3 years ago
Peer Review

Let­ters to the Ed­i­tor: Don't ex­pect a cor­re­la­tion be­tween an in­di­vid­ual drug's de­vel­op­ment cost and price

3 years ago
Letters to the Editor

Af­ter call­ing a lengthy time out on the de­vel­op­ment field, Al­lo­gene fi­nal­ly kicks off a land­mark PhII piv­otal

3 years ago
R&D
First page Previous page 448449450451452453454 Next page Last page
A service from the Financial Times